TNFRSF9 and colon carcinoma: Some of these combinations have potentially less autoimmune side effects than double immune-checkpoint blockade while still having beneficial effects, for example, combination therapy involving anti-CD137 and CTLA-4 blockade in MC38 colon carcinoma tumors and GL261 glioblastoma (115, 116).